These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 20977576

  • 1. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
    Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M.
    Diabetes Obes Metab; 2010 Dec; 12(12):1058-65. PubMed ID: 20977576
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.
    Ann Intern Med; 2007 Apr 03; 146(7):477-85. PubMed ID: 17404349
    [Abstract] [Full Text] [Related]

  • 4. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.
    Ann Intern Med; 2011 Jan 18; 154(2):103-12. PubMed ID: 21138825
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group.
    Lancet; 2010 Aug 07; 376(9739):431-9. PubMed ID: 20580422
    [Abstract] [Full Text] [Related]

  • 6. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.
    Diabet Med; 2011 Jun 07; 28(6):705-14. PubMed ID: 21434995
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B.
    Diabetes Obes Metab; 2015 Jul 07; 17(7):689-98. PubMed ID: 25846577
    [Abstract] [Full Text] [Related]

  • 10. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.
    Clin Ther; 2007 Jan 07; 29(1):139-53. PubMed ID: 17379054
    [Abstract] [Full Text] [Related]

  • 11. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec 07; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 12. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.
    Diabetes Care; 2005 May 07; 28(5):1092-100. PubMed ID: 15855572
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group.
    Diabetes Care; 2012 Feb 07; 35(2):252-8. PubMed ID: 22210563
    [Abstract] [Full Text] [Related]

  • 14. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov 07; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M.
    Diabetes Care; 2014 Aug 07; 37(8):2159-67. PubMed ID: 24879836
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.
    Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH.
    Curr Med Res Opin; 2008 Sep 07; 24(9):2437-47. PubMed ID: 18662495
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH, Song WL, Huang YY, Guo XH, Gao Y.
    Chin Med J (Engl); 2012 Aug 07; 125(15):2677-81. PubMed ID: 22931974
    [Abstract] [Full Text] [Related]

  • 18. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov 07; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 19. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group.
    Lancet; 2009 Jul 04; 374(9683):39-47. PubMed ID: 19515413
    [Abstract] [Full Text] [Related]

  • 20. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
    Ratner RE, Rosenstock J, Boka G, DRI6012 Study Investigators.
    Diabet Med; 2010 Sep 04; 27(9):1024-32. PubMed ID: 20722676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.